1. 1) Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia. 2010 ed., China Medical Science Press, Beijing, p. 49 (2010).
2. 2) Stiborová M, Frei E, Breuer A, Bieler CA, Schmeiser HH. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp. Toxicol. Pathol., 51, 421–427 (1999).
3. 3) Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M. Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet, 341, 387–391 (1993).
4. 4) Lemy A, Wissing KM, Rorive S, Zlotta A, Roumeguere T, Muniz MC, Decaestecker C, Salmon I, Abramowicz D, Vanherweghem JL, Nortier J. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am. J. Kidney Dis., 51, 471–477 (2008).
5. 5) Jelaković B, Karanovic S, Vukovic-Lela I, Miller F, Edwards KL, Nikolic J, Tomic K, Slade N, Brdar B, Turesky RJ, Stipancic Z, Dittrich D, Grollman AP, Dickman KG. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int., 81, 559–567 (2012).